||JIB-04 is a pan-selective Jumonji histone demethylase inhibitor.
||SP2509 is a specific histone demethylase LSD1 inhibitor(IC50 =13 nM).
||GSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e.
||GSK-J4 is a potent H3K27me3 demethylase inhibitor, with IC50s of 8.6 μM and 6.6 μM towards KDM6B and KDM6A respectively. It is the first selective inhibitor of the H3K27 histone
||CPI-455 is a specific KDM5 inhibitor.
||Daminozide is a plant growth regulator, selectively inhibits the KDM2/7 JmjC subfamily.
||KDM4D-IN-1 is a KDM4D inhibitor (IC50: 0.41±0.03 μM).
||OG-L002 is an effective and selective LSD1 inhibitor (IC50: 20 nM), showing 69- and 36-fold selectivity over MAO-A and MAO-B, respectively.
||IOX1 is the most effective broad-spectrum 2OG oxygenases(including the JmjC demethylases) inhibitor. The IC50 of IOX1 for KDM4A, KDM3A, is 0.6 and 0.1 uM, respectively.
||ML324(IC50=920 nM) is a specific inhibitor of jumonji histone demethylase (JMJD2).
||GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity
||ORY-1001 (RG-6016) is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor, with high selectivity against related FAD dependent aminoxidases with IC50 of
||GSK2879552 2HCl (1401966-69-5(free base))
||GSK2879552 is an orally available, irreversible inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.
||GSK-J4 is a cell permeable, potent and selective histone demethylase(JMJD3 )inhibitor. is an ethyl ester derivative of the GSK-J1 with an IC50 value greater than 50 μM in vitro.
||Seclidemstat is an effective LSD1 inhibitor, with a mean IC50 of 127 nM.
||ORY-1001, a Potent and Selective Covalent KDM1A/LSD1 Inhibitor, for the Treatment of Acute Leukemia.
||NCGC00244536 is a potent KDM4B inhibitor (IC50: 10 nM).
||Tranylcypromine (2-PCPA) hydrochloride
||Tranylcypromine Hydrochloride, a monoamine oxidase inhibitor, is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It is a propylamine fo
||Tranylcypromine is an inhibitor of monoamine oxidase (MAO) and lysine-specific demethylase 1 (LSD1) with a rapid onset of activity.
||GSK467 is a potent and selective inhibitor of KDM5 (JARID1)(Ki : 10 nM).
||T-3775440 hydrochloride is an irreversible inhibitor of lysine-specific histone demethylase (LSD1)(IC50 : 2.1 nM).
||(rel)-Tranylcypromine D5 hydrochloride
||(rel)-Tranylcypromine D5 hydrochloride is a deuterium labeled (rel)-Tranylcypromine hydrochloride. (rel)-Tranylcypromine hydrochloride is an irreversible, nonselective inhibitor of
||S 2101 is an inhibitor of lysine-specific demethylase 1 (LSD1)(IC50 of 0.99 μM, Ki of 0.61 μM and Kinact/Ki of 4560 M/s).
||T-448 free base
||T-448 free base is a specific, orally active and irreversible lysine-specific demethylase 1 (LSD1, an H3K4 demethylase) inhibitor(IC50 of 22 nM).
||T-448 is a specific, orally active and irreversible lysine-specific demethylase 1 (LSD1, an H3K4 demethylase) inhibitor(IC50 of 22 nM).
||GSK-J1 lithium salt
||GSK-J1 lithium salt is a potent inhibitor of me2-demethylases JMJD3/H3K27me3/KDM6B and UTX/KDM6A (IC50: 60 nM towards KDM6B).
||GSK 690 Hydrochloride
||GSK 690 is a reversible inhibitor of lysine-specific demethylase 1 (LSD1) (Kd: 9 nM; biochemical IC50: 37 nM).
||KDM5-IN-1 is an effective, selective, and orally bioavailable inhibitor of KDM5 (IC50: 15.1 nM).
||KDM5A-IN-1 is a potent and orally bioavailable inhibitor of pan-histone lysine demethylases 5 (IC50s: 45 nM, 56 nM, and 55 nM for KDM5A, KDM5B, and KDM5C) and (EC50: 960 nM for PC9
||Corin is a dual inhibitor of histone lysine-specific demethylase (LSD1) and HDAC (Ki(inact): 110 nM for LSD1; IC50: 147 nM for HDAC1).
||KF21213 shows a high affinity for the adenosine A2A receptors (Ki=3.0 nM). KF21213 is a highly selective ligand for mapping CNS adenosine A2A receptors.
||KF 13218 is a selective, potent and long lasting thromboxane B2 (TXB2) synthase inhibitor with an IC50 value of 5.3±1.3 nM.
||Kgp-IN-1 is an arginine-specific gingipain (Rgp) inhibitor.
||KHK-IN-2 is a selective and potent ketohexokinase (KHK) inhibitor with an IC50 of 0.45 μM.
||KI696 is a high affinity probe that disrupts the Keap1/NRF2 interaction. KI696 isomer is the less active isomer of KI696 .
||QC6352 is a selective and effective KDM4C inhibitor (IC50: 35 nM).
||LSD1-IN-5 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1. LSD1-IN-5 is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1
||LSD1-IN-6 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1. LSD1-IN-6 is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1),
||YUKA1 is a potent and cell-permeable Lysine demethylase 5A inhibitor (IC50: 2.66 μM) and less active on KDM5C (IC50, 7.12 μM). YUKA1 is inactive on KDM5B, KDM6A, or KDM6B.
||CPI-455 is a specific KDM5 inhibitor with IC50 value of 10 ± 1 nM for full-length KDM5A in enzymatic assays, elevating global levels of H3K4 trimethylation (H3K4me3) and decrease
||L-2-Hydroxyglutaric acid disodium
||L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) act
||AS-8351 is a histone demethylase inhibitor. It has been used in combination with CHIR99021, A 83-01, BIX01294, SC-1, Y-27632, OAC2, SU 16f, and JNJ-10198409 to induce reprogramming